ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models

Cancer Commun (Lond). 2022 Jun;42(6):567-571. doi: 10.1002/cac2.12282. Epub 2022 Mar 16.
No abstract available

Keywords: ABTL0812; Autophagy; Breast Cancer; Chemoresistance; TRIB3; Targeted Therapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Drug Resistance, Neoplasm
  • Humans
  • Linoleic Acids
  • Paclitaxel* / therapeutic use
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Linoleic Acids
  • ABTL0812
  • Paclitaxel

Associated data

  • ClinicalTrials.gov/NCT02201823
  • ClinicalTrials.gov/NCT03366480
  • ClinicalTrials.gov/NCT04431258